Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Neurotrophic Cochlear Implant for Severe Hearing Loss (NEUEAR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Denmark,Sweden,Germany,Austria,United Kingdom
Call:  (FP7-HEALTH-2012-INNOVATION-2, 2012)
Start date: 2012-09-01
End date: 2015-12-31
Duration (months): 40.0
Total project cost (EUR): 8335282.4
EU funding (EUR): 5843872.0
Participants: 5
Project status: CLOSED

Sixteen percent of adult Europeans suffer from hearing loss, great enough to adversely affect their daily life. Over the age of 80, 50% of the population is suffering from hearing loss. A large portion of this population is affected by sensoryneural hearing loss (SNHL), a consequence of a progressive degeneration of the primary auditory neurons (ANs), the afferent neurons of the cochlea. These ANs are the target cells of the neurotrophic cochlear implant – a neural prosthesis that will be designed by the partners of NeuEar to provide both electric auditory cues and regenerative neurotrophic factor(s) to severe-profoundly deaf patients. The ongoing degeneration of ANs that occurs over time is a limiting factor in current cochlear implant efficacy. The exogenous application of neurotrophic factors can prevent these degenerative changes. This project aims to develop an encapsulated cell (EC) therapy device capable of long-term intracochlear neurotrophin production in combination with a cochlear electrode implant. The aim is also to develop a versatile encapsulated cell implant that could be used to deliver regenerative factors to the cochlea even without the electrode part in future applications. The project brings together an SME capable of making clinically and regulatory compliant EC therapy devices with an industrial partner already on the market with a successful cochlear implant. These companies will work closely with two academic partners with expertise and resources to select, evaluate, and validate the neurotrophic cochlear implant. It is the intention of this consortium to make a clinically relevant implant with an associated preclinical package for regulatory submission over the next three years. Another SME will implement an efficient exploitation and dissemination structure, including a patent strategy to enable partnering and fund-raising for further clinical development, regulatory approval, commercialization, and marketing.

Keywords: deafness,regenerative medicine,encapsulated cell,cochlear implant,cell therapy,gene therapy,neurotrophic factors,sensorineural hearing loss,long-term safety
Clinical trial of gene therapy for MPS VI - a severe lysosomal storage disorder (MEUSIX)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,France,Italy,Türkiye,Netherlands,United States
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2017-11-30
Duration (months): 60.0
Total project cost (EUR): 7876955.0
EU funding (EUR): 5995041.0
Participants: 9
Project status: CLOSED

Mucopolysaccharidosis VI (MPS VI, or Maroteaux-Lamy syndrome; OMIM #253200) is a rare lysosomal storage disease caused by deficient activity of arylsulfatase B (ARSB). MPS VI is characterized by growth retardation, corneal clouding, cardiac valve disease, organomegaly, skeletal dysplasia, without central nervous system involvement. Thus, systemic therapies targeting peripheral organs have the potential to fully correct the MPS VI phenotype. Enzyme replacement therapy, the current treatment for MPS VI, requires weekly infusions of a costly enzyme and has limited efficacy on bone and corneal disease. Based on the encouraging preclinical results generated by our group, gene therapy based on a single intravascular administration of adeno-associated viral (AAV) vectors targeting liver has the potential to provide a lifelong source of ARSB. The MeuSIX consortium plans to conduct a multicenter phase 1/2 clinical trial to investigate the safety and efficacy of AAV-mediated gene therapy in patients with MPS VI. An orphan drug designation (ODD) has been obtained from both the European Medicinal Agency and the US Food and Drug Administration for the MPS VI therapeutic AAV vector. The results from this clinical trial proposed by the MeuSIX consortium has the potential to have a tremendous impact on the natural history of MPSVI and to significantly improve the quality of life of the affected patients. Moreover, the approach developed may facilitate the development of similar approaches for other inborn errors of metabolism.

Keywords: gene therapy,liver,aav,mucolysaccharidoses,lyssosomal storage diseases
Ultrafast quantum physics on the sub-cycle time scale (QUANTUMSUBCYCLE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Condensed matter physics
Countries involved: Germany
Call:  (ERC-2012-StG_20111012, 2012)
Start date: 2013-04-01
End date: 2018-03-31
Duration (months): 60.0
Total project cost (EUR): 1494564.0
EU funding (EUR): 1494564.0
Participants: 1
Project status: CLOSED

The physics of condensed matter depends on ultrafast dynamics of its atomic constituents. Femtosecond light pulses have been exploited to monitor these phenomena by stroboscopic means. Yet, the time resolution is limited by the duration of the intensity envelope of the light pulses used. We propose a new class of sub-cycle optics, which harnesses the absolute optical phase and amplitude of ultrashort transients to control condensed matter faster than an oscillation cycle of light. Merging latest terahertz technology with nanooptics, we tailor extreme electric and magnetic near-fields of phase-locked infrared pulses in all four spatio-temporal dimensions. This unprecedented laboratory allows us to pioneer long sought-after non-adiabatic quantum physics of all relevant elementary degrees of freedom: electronic charge and spin as well as photons. (i) Optical acceleration of electrons in the sub-cycle limit will permit to test yet unobserved key concepts of relativistic quantum transport, such as Zitterbewegung of Dirac fermions and Bloch oscillations in bulk semiconductors. (ii) We aim to switch the spin direction in magnetic materials by giant magnetic or electric fields, of 10 GV/m and several 10 Tesla, promising record control speeds and unique vistas onto the fastest magnetic elementary processes. (iii) By advancing the sensitivity of electro-optic sampling to the few-photon level the quantum nature of the oscillating carrier wave will be detected in the time domain. Spontaneous creation of photons out of quantum vacua, reminiscent of Hawking radiation of black holes, may be traced. The project breaks grounds for basic research, shedding new light onto the foundations of quantum electrodynamics, solid state physics and magnetism, as well as a new kind of field resolved quantum optics.

Keywords: phase-locked light pulses,nanoantenna,ultrabroadband terahertz science and technology,zitterbewegung,bloch oscillations,spin switching,field-sensitive quantum optics
SPECIFICALLY INTERACTING POLYMERS – From Selective Adhesion toward Specific Recognition (SIP)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Materials and Synthesis
Countries involved: Germany
Call:  (ERC-2012-StG_20111012, 2012)
Start date: 2013-01-01
End date: 2017-12-31
Duration (months): 60.0
Total project cost (EUR): 1499800.0
EU funding (EUR): 1499800.0
Participants: 1
Project status: CLOSED

The ability to control interactions in synthetic polymers as precisely as in proteins will have a significant impact on polymer and material sciences. The present proposal explores broadly applicable routes toward synthetic polymers having the capability of specifically interacting with distinct targets such as small molecules, surfaces, or material interfaces. Novel design strategies for peptide-polymer conjugates will be established, which broadly exploit combinatorial methods for the selection of suitable peptide segments. Understanding the requirements for specific interactions will ultimately enable the synthesis of non-peptidic block copolymers that can mimic specific peptide interactions. The striking opportunities that arise from the newly established platform of “specifically interacting polymers” will be demonstrated in three case-based studies on: (1) Specific solubilizers & transporters, which specifically host, transport and actively liberate problematic high-potential drugs. (2) Specific surface recognizers, which enable material-specific adhesion to generate, with office laser printers, penta-functional paper surfaces or 3D-channels. (3) Specific compatibilizers, which allow tailoring of internal material interfaces to fine-tune sustainable composites via specific interface design. This project will encourage the synthesis of next-generation functional polymers that offer exciting new possibilities for specific materials sciences.

Keywords: peptide-polymer conjugates,precision polymer synthesis,biomimetic polymers,advanced macromolecular engineering,tailored polymer interactions,polymer assembly
Enabling the European Nanomedicine Area until 2020 (NANOMED2020)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Germany,Switzerland,Spain,Germany,France,Italy,Norway
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-09-01
End date: 2014-02-28
Duration (months): 18.0
Total project cost (EUR): 620087.5
EU funding (EUR): 499647.2
Participants: 7
Project status: CLOSED

Nanotechnology applied to medical applications, Nanomedicine, is one of the most important emerging areas of health research and is understood to be the most promising out of the six KETs, for innovative devices and materials for personalised, targeted and regenerative medicine. However, due to the complexity of technologies and medical application areas Nanomedicine requires many different so far independent stakeholders from academia, industry and regulatory bodies. Due to the diversity of stakeholders the partners of this project will initiate a strong coordination and support action to build a pertinent European Nanomedicine community involving all key players necessary to define the resources, gaps and needs for development and implementation of nanomedical research into marketable innovations to be used by doctors for the benefit of patients. The implementation concepts will also target the initiation of Public Private Partnerships for the creation of novel infrastructures and innovative funding programmes. Nanomedicine research is growing fast in many countries. Therefore, the project consortium will initiate international collaborations in the Nanomedicine area, especially the coordination of international regulation of Nanomedicine products. The partners involved in the project represent major European networks combining academia, industry, clinicians and public authorities. Based on this strong partnership and after integration of further national and European initiatives the output of this support action will be a strong, established partnership of relevant stakeholders in identified key areas of Nanomedicine with new concepts for translation of nanomedical innovations into clinical practice and efficient and transparent communication channels. This will make Nanomedicine an important contributor to the future European healthcare system with a beneficial impact on improved treatment for patients and on social challenges such as ageing population.

Keywords: nanomedicine,clinics,medicine,nanotechnology,health,diagnostics,therapeutics,personalised medicine,regenerative medicine,european strategy,community building,kets,translation,industry
Support for international rare disease research to serve the IRDiRC objectives (SUPPORT-IRDIRC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Coordination and support actions
Countries involved: France
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2018-12-31
Duration (months): 75.0
Total project cost (EUR): 2231965.52
EU funding (EUR): 2000000.0
Participants: 2
Project status: CLOSED

Research into rare diseases (RD) is badly needed as many patients still lack a proper diagnosis and most of them are left without an effective treatment. In addition, research in this area is very relevant from a scientific point of view as RD are model diseases for more common disorders and are strong drivers of innovation. However, research in this field faces some specific constraints stemming from the low prevalence that represents the defining characteristic of RD, the sheer number of RD and their high phenotypic heterogeneity. It is now recognised that a global coordination of efforts is necessary to avoid duplication, fragmentation, redundancy and gaps in RD research, and to ensure that the results obtained can be rapidly translated into diagnostics and treatments to benefit patients. This awareness has led to the launch of IRDiRC, whose mission is to coordinate and foster international collaborative research on RD, with the ambitious objectives of developing 200 new therapies and producing diagnostic tools for a majority of RD by 2020. The objective of SUPPORT-IRDiRC is to provide organisational and communication support to IRDiRC and thereby contribute to the development of policies and guidelines aimed at accelerating research on RD and reinforcing international research cooperation. To this aim, SUPPORT-IRDiRC has gathered together a group of motivated and highly experienced investigators who will work together during 6 years to help IRDiRC members remain on the right track in order to reach its ambitious objectives. SUPPORT-IRDiRC will work in close collaboration with the European Commission, research funding agencies from all countries involved, as well as with research projects contributing to the achievement of IRDiRC objectives, with a special focus on projects funded under HEALTH-2012.2.1.1-1-B & C, to which we will make sure that key results are shared and widely disseminated.

Keywords: rare diseases,irdirc,support
Formulating new Goals for global health, and proposing new Governance for global health that will allow the achievement of these goals (GO4HEALTH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: Belgium,Germany,United States,United Kingdom,Kenya,Bangladesh,United Kingdom,Australia,Canada,United Kingdom,South Africa,Germany,Uganda,Guatemala
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-09-01
End date: 2016-02-29
Duration (months): 42.0
Total project cost (EUR): 2806818.8
EU funding (EUR): 1998222.0
Participants: 14
Project status: CLOSED

The MDGs succeeded in generating consensus on and mobilising resources towards agreed goals. They were less successful at clarifying responsibilities for achieving them. The MDG target on sharing global health innovation is particularly ambiguous about the allocation of responsibilities. The members of the consortium behind this proposal assume that the new goals for global health will need to be based on a broad global consensus on the goals, on accepted national and international responsibilities to achieve those goals, and on the kind of governance that is needed to ensure accountability for accepted responsibilities. They believe that the internationally agreed right to health provides a useful point of departure for the formulation of such a global consensus, that the goals should incorporate universal coverage, and that community input is critical to designing the goals. Consortium members will: * Assess the achievements and shortcomings of the MDG approach; * Consult communities whose health is most compromised on their essential needs and their perception of their entitlements under the right to health; * Assess the capacity of low and middle income countries to meet those needs and entitlements, including to identify where international assistance (financial and technical) or cooperation (on sharing innovation or avoiding the brain drain of health workers) is needed; * Analyse the international political economy of global health and global governance for health, to formulate international responsibility for global health; * Analyse, clarify, and re-affirm national responsibility for health, in the light of international responsibility for global health; * Propose new goals for global health, clarifying national and international responsibilities; * Provide suggestions for governance for global health to effectuate these responsibilities.

Keywords: global health,mdgs,innovation,global health governance,human rights,shared responsibility,community consultations
Methods for Integrated analysis of Multiple Omics datasets (MIMOMICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Belgium,United Kingdom,United Kingdom,Italy,Germany,Finland,Croatia,Germany,United Kingdom,Israel,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2017-09-30
Duration (months): 60.0
Total project cost (EUR): 7883081.13
EU funding (EUR): 5993308.0
Participants: 15
Project status: CLOSED

MIMOmics develops statistical methods for the integrated analysis of metabolomics, proteomics, glycomics and genomic datasets in large studies. Our project is based on our involvement in studies participating in EU funded projects, i.e. GEHA, IDEAL, Mark-Age, ENGAGE and EuroSpan. In these consortia the primary goal is to identify molecular profiles that monitor and explain complex traits with novel findings so far. Support for methodological development is missing. The state-of-the-art methodology does not match by far the complexity of the biological problem. Complex data are being analysed in a rather simple way which misses the opportunity to uncover combinations of predictive profiles among the omics data. The objectives of MIMOmics are: to develop a statistical framework of methods for all analysis steps needed for identifying and interpreting omics-based biomarkers; and to integrate data derived from multiple omics platforms across several study designs and populations. Specific steps include: experimental design; pipelines for data gathering; cleaning of noisy spectra; predictive modeling of biomarkers; meta analysis; and causality assessment. To enhance our understanding, systems approaches will be considered for pathways and structural modelling of biological networks. The major challenge in the joint analysis of omics datasets will be to develop methods that deal with the high dimensionality, noisy spectral data, heterogeneity, and structure of these datasets. To perform these tasks successfully we bring together established EU academic and industrial researchers in metabolomics, glycomics, biostatistics, bioinformatics, scientific computing and epidemiology, with complementary expertise. A key feature of our project is the validation of novel methodology by performing a proof of principle (Metabolic Health) . Special effort will be made for rapid uptake of methods by communication with associated consortia and development of user-friendly software

Keywords: metabolomics,proteomics,glycomics,genomics,biostatistics,machine learning,system approaches,high dimensional data,noisy spectra,heterogeneity,software development,epidemiology
Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery (MOTIF)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,United States,Czechia,Italy,United Kingdom,France,Belgium
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2016-03-31
Duration (months): 42.0
Total project cost (EUR): 7612908.87
EU funding (EUR): 5818937.0
Participants: 9
Project status: CLOSED

The 40% protection against HIV-1 infection with vaginally-applied tenofovir gel demonstrated in the CAPRISA004 trial, has emphasized development of anti-retroviral (ARV)-based microbicides. Combining ARVs in a single product may provide increased protection. Development of a generally applicable formulation platform for combining ARVs (even if chemically incompatible) and understanding of the processes (drug uptake, efflux and metabolism) that determine tissue levels of microbicide are two important gaps in knowledge necessary for microbicide development. We propose to identify drug uptake and efflux transporters in cervicovaginal tissue and to use this information together with data on drug transporters from colorectal tissue to develop improved in vitro cell-based systems for biopharmaceutical screening. We also propose to develop a standardized drug encapsulation and formulation system that will allow insertion of any drug combinations. Informed by data on drug uptake, efflux and metabolism, these formulations will be further modified either by beneficial drug-drug interactions or by including selective inhibitors or inducers of drug transporters to optimize drug concentrations at target tissue sites. Comparative studies of drug transporters will also be performed in two important animal models, namely non-human primates (virus challenge ) and rabbit (regulatory toxicology). Optimised drug formulations will be tested in vitro and will undergo pharmacokinetic and pharmacodynamics studies in the animal models. Project outcomes will include a detailed description of drug transport in colorectal and cervicovaginal tissue to provide a rational basis for microbicide formulation, platform technology for formulating microbicide combinations optimized for vaginal or rectal delivery and prototype microbicide products for phase I clinical trial. The proposal should impact significantly on development of improved microbicides to prevent HIV infection.

Keywords: microbicides,hiv-1,drug transporter,formulation,in vitro epithelial models,biopharmaceutical screening,pharmacokinetic/pharmacodynamic studies,arv combination microbicide